#1 Clinical Trials Search in Europe

A study to examine how the body processes and removes DC-806 in healthy male volunteers

1 1 1

What is this study about?

This study aims to investigate how the body processes and eliminates a new substance. The research focuses on a drug known as DC-806 and its labeled version, [14C] DC-806, which contains a traceable marker to help track its movement. This investigation involves healthy individuals to understand the pharmacokinetics, which is the study of how a substance moves through the body, and the metabolism, which is the process by which the body breaks down substances.

Participants will be given a single dose of the medication in the form of an oral film-coated tablet or a capsule. During the study, researchers will monitor the excretion, or the process of eliminating substances from the body, by collecting urine and feces. The study also tracks the presence of the substance in the blood and plasma, which is the liquid part of the blood, to determine how the drug is absorbed and distributed over time.

Who Can Join the Study?

  • You must be a male.
  • You must be between 18 and 55 years old at the time of the initial screening.
  • You must be in good physical and mental health, which will be confirmed by your medical history, a physical exam, laboratory tests, an electrocardiogram (a test that records the electrical activity of your heart), and your vital signs (measurements such as blood pressure and heart rate).
  • You must have a body mass index (a measure of your body weight in relation to your height) between 18.0 and 30.0 kg/m2.
  • You must weigh at least 50 kg.
  • You must be a healthy individual.
  • You must be willing and able to sign the informed consent form, which is a document that explains all details of the study before you agree to participate.
  • You must agree to avoid foods and drinks containing methylxanthine (found in coffee, tea, cola, chocolate, and energy drinks) and grapefruit (including juice) starting 48 hours before arriving at the site and for the entire time you are staying there.
  • You must agree to avoid any strenuous physical exercise (very heavy or intense physical activity) starting 96 hours before arriving at the site and during your stay.
  • You must agree to avoid alcohol starting 48 hours before the screening and for the duration of your stay.
  • You must stop all prescribed medications at least 14 days before arriving at the site.
  • You must stop all over-the-counter medications (medicines you can buy without a doctor’s note), vitamins, food supplements, or herbal medications at least 7 days before arriving at the site, though occasional use of acetaminophen/paracetamol (common pain relievers) is allowed.
  • You must agree to use adequate contraception (methods to prevent pregnancy) and not donate sperm from the time you arrive until 90 days after receiving the study drug. This includes using methods like a vasectomy (a permanent procedure for men to prevent pregnancy), tubal ligation (a permanent procedure for women), hormonal contraceptives (birth control pills or similar), or an intrauterine device (a device placed in the uterus) combined with a condom.
  • If your partner is not able to become pregnant or is male, you must use a condom from 48 hours before the study until at least 30 days after receiving the study drug.

Who Cannot Join the Study?

  • You are an employee of the company conducting the study or the company that made the drug.
  • You have taken part in another drug study (a medical test involving new medicines) within the last 30 days.
  • You have participated in 4 or more other drug studies in the last 12 months.
  • You have donated or lost more than 450 mL of blood (the fluid that carries oxygen in your body) in the last 60 days.
  • You have donated or lost more than 1.5 liters of blood in the last 10 months.
  • You have had a serious or sudden illness (a period of being unwell) within the last 5 days that might affect safety checks.
  • You have been exposed to a certain amount of radiation (energy that can travel through the air, often used in medical scans) in a previous study within the last 1 to 3 years, depending on the specific amount.
  • You have had exposure to radiation for medical testing (other than dental X-rays or simple chest X-rays), for your job, or in another study within the last year.
  • Your veins (the tubes that carry blood back to your heart) are not suitable for receiving medicine or having blood taken.
  • You have any other medical condition or have received any other therapy (medical treatment) that the doctor believes could interfere with the results or your safety.
  • You have a history of allergies (harmful reactions to certain substances) to food or medicine.
  • You have an irregular defecation pattern, which means you go to the bathroom to pass waste less than once every two days on average.
  • You smoke more than 5 cigarettes, 1 cigar, or 1 pipe every day.
  • You are unable or unwilling to stop using tobacco products (such as cigarettes) for 48 hours before the study starts and while staying at the clinic.
  • You have a history of alcohol abuse (drinking too much alcohol) or drug addiction (including cannabis) within the last year.
  • You test positive for drugs or alcohol (including substances like cocaine, cannabis, or certain medicines) during the initial medical screening.
  • You drink more than an average of 24 units of alcohol per week.
  • You test positive for Hepatitis B, HCV (Hepatitis C virus), or HIV (a virus that affects the immune system).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Pvdnciyxgiobya Rjkdtuvd Awthqmudic Ghsin Bhtc Groningen The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not recruiting
14.08.2023

Trial locations

Investigated drugs:

DC-806 is an experimental medication being tested to see how the body absorbs, uses, and gets rid of it. In this study, it is taken by mouth to help researchers understand how it moves through the body and how it is broken down.

[14C]-DC-806 is a special version of the experimental drug that contains a tiny, safe amount of a radioactive marker. This marker acts like a tracer, allowing scientists to track exactly how the medication travels through the body and where it is eventually released, such as through urine or stool.

Investigated diseases:

Since the provided source data specifies that the study is conducted on “Healthy” participants and does not list any specific medical conditions or diseases being studied, there are no diseases to describe.

Trial ID:
2023-505367-36-00
Protocol code:
DCE806102
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

    Recruiting

    3 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +6